News Archive

The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.

Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.

By evaluating patient-reported and electronic health record data, the pragmatic clinical study adds important real-world evidence to inform clinical practice.

EDITORS' NOTE: This story was updated January 19, 2021 when the study was published in Journal of the American Medical Association.

The ISCHEMIA trial made headlines last year at the American Heart Association 2019 Scientific Sessions, where primary results were presented indicating that invasive heart procedures may not reduce

Attendees to a January 2019 DCRI Think Tank outlined recommendations for optimizing pragmatic clinical trials and weighing risks and benefits of innovative trial designs.

An analysis of a study called Mission: Lifeline STEMI Accelerator II found that when patients experiencing an ST-elevation myocardial infarction present in facilities not capable of performing percutaneous intervention, the time between their arrival and cath lab activation is an important quality metric to direct timely reperfusion.

DCRI faculty recently contributed to a paper advocating for a focus on pain management so that progress in combatting the U.S. opioid crisis is not lost in the midst of the COVID-19 pandemic.

Study results recently published in the Journal of the American College of Cardiology: Heart Failure build on novel research investigating the efficacy of blocking the splanchnic nerve to treat patients with heart failure. The study, which was led by former DCRI fellow Marat Fudim, MD, MHS, included 15 patients who underwent a temporary medication-induced splanchnic nerve blockage and required them to complete an exercise twice—once prior to the blockage, and once after the blockage.

Although valve failure is rare, patients who had to undergo re-operation were at risk of negative outcomes.